The change ratio of serum CCL22 in CTCL patients who responded to bexarotene therapy was significantly lower than that in CTCL patients who showed progressive disease by 4 weeks after starting bexarotene therapy (Figure 3A). This evidence concerns the gene CCL22 and primary cutaneous T-cell non-Hodgkin lymphoma.